MAXIM Group Resumes Coverage on SINTX Technologies with Buy Rating and $6 Price Target
MAXIM Group Resumes Coverage on SINTX Technologies with Buy Rating and $6 Price Target
June 4, 2026
MAXIM Group Resumes Coverage on SINTX Technologies with Buy Rating and $6 Price Target
Independent analyst coverage highlights SINTX’s progress toward becoming a diversified silicon nitride biomaterials platform company, citing the company’s FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System, expanding commercialization strategy, and opportunities across orthopedic, antipathogenic, and patient-specific implant applications. The report also notes SINTX’s proprietary manufacturing capabilities, 3D-printing initiatives, and silicon nitride technology platform as potential drivers of future growth.
